ARCH-backed Re­silience nabs its lat­est fi­nanc­ing round, putting to­geth­er a mas­sive $625M Se­ries D

Since emerg­ing from stealth in late 2020, Re­silience has me­thod­i­cal­ly built up its cash re­serves and inked nu­mer­ous col­lab­o­ra­tion deals. On Mon­day, the com­pa­ny an­nounced its lat­est move.

The Bob Nelsen-backed biotech re­vealed plans for its Se­ries D ear­ly Mon­day morn­ing, putting to­geth­er $625 mil­lion to fur­ther its mis­sion of be­com­ing the “Fox­conn” of biotech. Mon­day’s new cash will be used to con­tin­ue in­vest­ing in its in­fra­struc­ture through more deals, po­ten­tial ac­qui­si­tions and R&D ex­pan­sion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER